Sarfaraz Niazi, PhD, urges the FDA to let the USPharmacopeia (USP) create product release specifications for biosimilars to cut costs, speed development, and enhance accessibility.
My citizen petitioned the FDA to remove the ban on the US Pharmacopoeia (USP) to create monographs for biosimilars, fearing that the monographs may create intellectual property issues based on the historical understanding of monographs.
To overcome this, I published a long paper and replaced monographs with product release specifications that would remove a significant burden in developing biosimilars. The FDA has responded, asking for more time. I have returned my answer, asking why the timing would be an issue.
I believe this is straightforward: let the USP create release specifications and supply validated test methods. This could remove the need to secure multiple batches of the reference product and cut down the time and cost of development by 90%, essentially bringing biosimilars into the category of biogenerics.
I have the full concurrence of the US Pharmacopeia leadership to my proposal, and we are even going ahead with this plan with or without the FDA concurrence and then challenging the FDA as to why this approach should not be acceptable. My petition has no support from big pharmaceutical companies for 2 reasons. First, they are now in the biosimilar field and own the reference product. It is time for science to prevail. It is time for those needing biosimilars to rise and help me get this change quickly.
Once the FDA agrees with my proposal, hopefully, we won’t need to discuss the affordability of biosimilars, and we will no longer be complaining about why only a few of the over 100 biologic drugs that are off patent have biosimilars. I believe that this change will revolutionize the accessibility to biologic drugs worldwide.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
BioRationality: No More Biosimilars—Just Biogenerics
February 3rd 2025Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, recognizing them as "biogenerics" since physicochemical and in vitro biological comparisons are sufficient to ensure safety and efficacy.